Notify your doctor immediately if you develop a skin rash, itching, burning, redness, pain, swelling in or around the eyes or vision problems while using this medication.

Watch the latest videos on YouTube.com

Precautions:

This medication should be used only if clearly needed during pregnancy or while breast-feeding.

Discuss the risks and benefits with your doctor.

Tell your doctor if you have any eye problems or allergies, especially to any antibiotics.

In Canada call 1-800-668-1507.

Generic Name: Vidarabine

Vira-A 3% Ointment - Prescription

Vidarabine

VIROLOGY: Mechanism of Antiviral Action: Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).
Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced HIV infection.
peak steady-state plasma acyclovir concentrations observed in humans treated with 30 mg/kg per day (10 mg/kg every 8 hours, dosing appropriate for treatment of herpes zoster or herpes encephalitis), or 15 mg/kg per day (5 mg/kg every 8 hours, dosing appropriate for treatment of primary genital herpes or herpes simplex infections in immunocompromised patients).

http://www.fda.gov/cder/ogd/rld/18603S19.PDF
Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see CLINICAL PHARMACOLOGY: Pharmacokinetics). acyclovir, drug.

Vidarabine

The review found no significant difference between a topical interferon and a topical antiviral agent in healing after 7 days, but found that a topical interferon increased healing after 14 days.
Topical antiviral agents One systematic review has found that topical antivirals (idoxuridine or vidarabine) increase healing after 14 days compared with placebo, and that trifluridine or aciclovir increase healing compared with idoxuridine after 7 and 14 days.

http://www.clinicalevidence.com/ceweb/conditionpdf/0707.pdf
We found one RCT (104 people with herpes simplex virus stromal keratitis [see glossary, p 969] receiving concomitant topical corticosteroids and a topical antiviral agent [trifluridine]) of oral aciclovir.12 The primary outcome was time to treatment failure, defined as worsening or no improvement of stromal keratitis or an adverse event. treatment, antivirals.

Vidarabine

In the present study, effectiveness of topical vidarabine or subsequent 5-fluorouracil (5-FU) administration was examined against persistent genital human papillomavirus (HPV) infection after local surgery.
Thirty patients underwent local eradication treatment of uterine cervical intra-epithelial neoplasia (CIN) and stage Ia1 uterine cervical cancers.
The purpose of this study was to evaluate the effectiveness of topical vidarabine, and 5-FU for vidarabine-resistant cases for persistent HPV-positive infection after local eradication of CINs and uterine cervical stage Ia1 (FIGO).

http://147.52.72.117/OR/2003/volume10/number5/1437.pdf
Approximate 1.5 g of vidarabine ointment (Mochida Co., Tokyo, Japan) was topically applied once a week for four weeks around the uterine cervices, fornices and the vagina. HPV, Gynecol.

arasena Vidarabine

Arasena-A, an antiviral agent, is indicated for herpes zoster, herpes simplex and herpes simplex encephalitis.

http://www.mochida.co.jp/english/pdf/arasena.pdf
Arasena-A Ointment is the first topical antiviral drug developed in Japan. herpes simplex, vidarabine.